ARCHIVES

DCT Board Okays Contract Recompetitions, But Litton Bionetics May Be Barred From Two Supporting Gall’s Lab, Plus FCRF Program

This article is from The Cancer Letter archive.

Vol. 11 No. 41 | October 25, 1985

Download PDF Visit The Full Archive

Related Articles

Femara Better Suppressor Of Estrogen, Study Finds

February 22, 2002

Drug Cleared For GIST And Kidney Cancer, FDA’s First Two-Indication Cancer Approval

January 27, 2006

New Two-Step Matching Process Increases Success of Transplants

September 30, 2011

Eight Probable Minority CCOP Awardees Lister; NCI May Award As Many As 12, With 220 Payline

June 1, 1990

NCI to Fund 122 More Grants in FY04

March 28, 2003

Funding Opportunity: DOD Offering 10.5 Million For Lung Cancer Research

May 30, 2014